Tuesday, Jan 21, 2025 · SEC filings

What the smart money revealed on Jan 21

Real insider buys10insiders · $2.02M
Real insider sales56insiders · $29.8M
Fund 13Fs filed—not loaded for this day
Activist 13Ds filed—not loaded for this day

388 insider filings came in. We hid 37 planned (10b5-1) sellers and 274 people whose filings were routine, like grants and tax withholding.

trending_up

Goldman Sachs Group (GS) Director Kevin Johnson bought $1.49M

2,400 shares on the open market. Not a grant or an option exercise.

Real buy Form 4 Traded Jan 17
$1.49M
trending_up

Constellation Brands (STZ) Director William Giles bought $186K

1,000 shares on the open market. Not a grant or an option exercise.

Real buy Form 4 Traded Jan 17
$186K
trending_up

Credit Suisse High Yield Bond Fund (DHY) Trustee Laura DeFelice bought $121K

56,801 shares on the open market. Not a grant or an option exercise. Their past buys: 2 of 4 checked quarters beat the typical stock 6 months later.

Real buy Form 4 Past buys: 2 of 4 beat Traded Jan 21
$121K
trending_up

Credit Suisse Asset Management Income Fund (CIK) Director Laura DeFelice bought $119K

40,766 shares on the open market. Not a grant or an option exercise. Their past buys: 2 of 4 checked quarters beat the typical stock 6 months later.

Real buy Form 4 Past buys: 2 of 4 beat Traded Jan 21
$119K
trending_down

Ryan Specialty (RYAN) Director Nicholas Cortezi sold $7.01M

Not marked as a planned 10b5-1 sale. Sold 40% of the shares they held directly. Still holds 155,443 shares.

Real sale Form 4 Sold 40% of stake Traded Jan 16–21
$7.01M
trending_down

Schlumberger Limited (SLB) EVP Mogharbel Al sold $5.43M

Not marked as a planned 10b5-1 sale. Sold 40% of the shares they held directly. Still holds 184,626 shares.

Real sale Form 4 Sold 40% of stake Traded Jan 21
$5.43M
trending_down

Mirum Pharmaceuticals (MIRM) Chief Medical Officer Joanne Quan sold $320K

Not marked as a planned 10b5-1 sale. Sold 55% of the shares they held directly. Still holds 5,649 shares.

Real sale Form 4 Sold 55% of stake Traded Jan 17
$320K
Show 6 more real buys
Show 53 more real sales
SNX TD SYNNEX · Hyve Solutions Executive Dennis Polk · Traded Jan 16
$3.01M
SLB Schlumberger Limited · EVP and CFO Stephane Biguet · Traded Jan 21
$1.97M
SLB Schlumberger Limited · Chief Legal Officer and Sec Dianne Ralston · Traded Jan 21
$1.9M
SLB Schlumberger Limited · Director Vijay Kasibhatla · Traded Jan 21
$1.1M
SRRK Scholar Rock Holding · CEO Jay Backstrom · Traded Jan 16
$986K
FIVE Five Below · CAO Eric Specter · Traded Jan 16–17
$927K
SLB Schlumberger Limited · Chief Accounting Officer Howard Guild · Traded Jan 21
$595K
KRUS Kura Sushi USA · Director Seitaro Ishii · Traded Jan 16
$574K
DAL Delta Air Lines · SVP William Carroll · Traded Jan 17
$555K
SRRK Scholar Rock Holding · COO and CFO Edward Myles · Traded Jan 16
$554K
PLAB Photronics · CEO Kang Lee · Traded Jan 16–17
$458K
TYRA Tyra Biosciences · Director Nina Kjellson · Traded Jan 16–21
$410K
SRRK Scholar Rock Holding · General Counsel Junlin Ho · Traded Jan 16
$400K
AIR AAR · Chairman John Holmes III · Traded Jan 17
$354K
PLMR Palomar · CEO and Chairman Mac Armstrong · Traded Jan 15
$345K
SRRK Scholar Rock Holding · Chief Scientific Officer Mo Qatanani · Traded Jan 16
$325K
SLB Schlumberger Limited · VP Controller Ugo Prechner · Traded Jan 21
$309K
SRRK Scholar Rock Holding · Chro Caryn Parlavecchio · Traded Jan 16
$284K
SRRK Scholar Rock Holding · Chief Medical Officer Jing Marantz · Traded Jan 16
$250K
APLS Apellis Pharmaceuticals · CEO Cedric Francois · Traded Jan 17
$180K
SRRK Scholar Rock Holding · Chief Commercial Officer Tracey Sacco · Traded Jan 16
$172K
TRAK ReposiTrak · CEO Randall Fields · Traded Jan 21
$163K
AURA Aura Biosciences · Officer Pinos de los · Traded Jan 21
$122K
SNX TD SYNNEX · Director Ann Vezina · Traded Jan 16
$114K
OWLT Owlet · President and CRO Jonathan Harris · Traded Jan 7–16
$106K
OFIX Orthofix Medical · CFO Julie Andrews · Traded Jan 16
$83.3K
SGHT Sight Sciences · President and CEO Paul Badawi · Traded Jan 16
$72.5K
APLS Apellis Pharmaceuticals · General Counsel David Watson · Traded Jan 17
$65.9K
APLS Apellis Pharmaceuticals · Chief Commercial Officer Adam Townsend · Traded Jan 17
$65.9K
PGY Pagaya Technologies · President Sanjiv Das · Traded Jan 17
$64.4K
APLS Apellis Pharmaceuticals · Chief Technical Officer Nur Nicholson · Traded Jan 17
$64.3K
FSLY Fastly · CFO Ronald Kisling · Traded Jan 16
$57.1K
DAKT Daktronics · VP of Manufacturing Matthew Kurtenbach · Traded Jul 12–17
$56.6K
APLS Apellis Pharmaceuticals · Chief Medical Officer Caroline Baumal · Traded Jan 17
$55.5K
APLS Apellis Pharmaceuticals · CFO Timothy Sullivan · Traded Jan 17
$51.8K
AEO American Eagle Outfitters · Director Cary McMillan · Traded Jan 16
$48K
SWZ Swiss Helvetia Fund · Director Phillip Goldstein · Traded Jan 17
$38.3K
APLS Apellis Pharmaceuticals · Chief People Officer Karen Lewis · Traded Jan 17
$37.2K
APLS Apellis Pharmaceuticals · Chief Business and Strat Officer Mark DeLong · Traded Jan 17
$37K
APLS Apellis Pharmaceuticals · Chief Scientific Officer Pascal Deschatelets · Traded Jan 17
$22.5K
APLS Apellis Pharmaceuticals · VP/Chief Accounting Officer James Chopas · Traded Jan 17
$21.4K
ABEO Abeona Therapeutics · Director Mark Alvino · Traded Jan 21
$20.4K
SGHT Sight Sciences · Chief Legal Officer Jeremy Hayden · Traded Jan 17
$19.2K
SGHT Sight Sciences · CTO David Badawi · Traded Jan 17
$15.1K
AURA Aura Biosciences · Vice President Amy Elazzouzi · Traded Jan 21
$7.68K
BKE Buckle · President and CEO Dennis Nelson · Traded Jan 17
$4.8K
CBUS Cibus · Director Gerhard Prante · Traded Jan 17
$2.88K
ACCD Accolade · CEO Rajeev Singh · Traded Jan 17
$2.12K
ACCD Accolade · President Robert Cavanaugh · Traded Jan 17
$1.28K
ACCD Accolade · CFO Stephen Barnes · Traded Jan 17
$1.06K
OWLT Owlet · CFO Amanda Crawford · Traded Jan 16
$783
ESPR Esperion Therapeutics · Chief Commercial Officer Eric Warren · Traded Jan 17
$278
ESPR Esperion Therapeutics · CFO Benjamin Halladay · Traded Jan 17
$20

13F season

Holdings as of Dec 31, 2024 are due Feb 14

81 funds have filed so far. 58 filed for the quarter before.

Biggest real insider buys, Jan 15–21

Open-market buys by officers and directors, filed in the 7 days up to Jan 21.

Where this data comes from. Insider trades, fund holdings, activist stakes and company results come from public SEC EDGAR filings (Forms 4, 13F, 13D/13G, 10-Q and 8-K). Congress trades come from the STOCK Act reports members file with the House Clerk and the Senate. Daily closing prices come from post-no-preference/stocks on DoltHub, a community-run database shared under CC BY-SA 4.0; the prices we show stay under that license. They are each day's close, not live or official exchange prices.

This is data, not investment advice. About StockToast · Your watchlist